We are committed to
the discovery and
development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. BT-11, the Company’s lead asset, is completing a Phase 2 trial in mild to moderate ulcerative colitis (UC) in the U.S. Europe and Russia, with plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn’s disease (CD). BT-11 is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.

View More

Home Illustration

Reprogramming Immune Responses in Autoimmune Diseases

Reprogramming Immune Responses in Autoimmune Disease

The Company’s advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified two novel pathways currently in clinical development: LANCL2 and NLRX1. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. NLRX1, a second pathway discovered by Landos, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments.

View More

Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD

For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. The Company’s therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.

At Landos Biopharma, our mission is to
be bold and uncover new mechanisms of
treating autoimmune disease.


  • 7/14

    Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease
    Read More
  • 5/12

    Landos Biopharma to Present at Two Upcoming Investor Conferences
    Read More
  • 3/24

    Landos Biopharma to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
    Read More